Vaccines

Enhance vaccine production with UniFuge®, ViaFuge®, and PowerFuge®. These centrifuges are designed for reliable, scalable vaccine development, offering flexibility for both live virus and recombinant vaccines.

How It Works

One cell processing platform for the full cell therapy development cycle

CARR’s centrifuge platforms use tubular bowl technology for gentle, low-shear separation, crucial for preserving cell viability in live virus vaccines and removing debris in recombinant vaccines. UniFuge and ViaFuge handle live virus applications, while PowerFuge manages complex solids in traditional vaccine production. All models support reliable, contamination-free processing.

Connect with an Expert

Cell Banking

Securely harvests and stores high-viability cells for future vaccine production, ensuring consistent quality and reproducibility across batches.

Gene Editing

Supports efficient recovery of genetically modified cells, critical for vaccine production involving gene-edited viral vectors or recombinant proteins.

Seed Train

Scalable processing efficiently separates and concentrates cells, preparing them for transfer to larger bioreactors for further expansion.

Intensification

Media exchange and optional washing maintain cell health for n-1 intensification, enabling advanced manufacturing strategies.

Live Virus Harvest

Low-shear processing with UniFuge and ViaFuge maximizes viable cell recovery, preserving the integrity of sensitive virus cultures during harvest.

Recombinant Vaccine Harvest

PowerFuge ensures high recovery and purity of recombinant proteins, minimizing impurities while maintaining product quality for protein-based vaccines.

Key Benefits

Benefits of using CARR Biosystems for Vaccines

High Cell Recovery
  • Efficient recovery of viable cells to maintain potency and yield
  • Gentle, low-shear processing minimizes cell damage, preserving viability
Optimized Solid Handling
  • Ability to process challenging materials like polysaccharides and recombinant proteins
  • High-G force enables effective clarification of sub-micron particles
Closed System Processing
  • Closed-system design reduces contamination risks for safe vaccine production
  • Safely handles hazardous processing of materials like ethanol
Enhanced Versatility
  • Products to support both live virus and recombinant protein vaccine production
  • Provide consistent results across various vaccine types and production stages

Endorsements

See what people are saying about Vaccines

Frequently Asked Questions (FAQs) About Vaccines

How do CARR centrifuges handle hazardous processing and difficult materials?

CARR centrifuges’ closed system design enables hazardous processing like ethanol drying and handles challenging materials such as fumed silica. During ethanol drying for polysaccharide production, the closed system minimizes exposure and risk. For difficult solids like fumed silica, CARR centrifuges are engineered to prevent clogging and ensure smooth, continuous operation.

What are the key advantages of tubular bowl centrifugation for vaccine production?

Tubular bowl centrifugation offers gentle separation of cells and solids, which is crucial for maintaining cell viability in live virus vaccines and efficiently removing debris in recombinant vaccine production.

How scalable are CARR centrifuge systems for vaccine production?

CARR centrifuge systems are designed to scale seamlessly from small-scale research to large-scale manufacturing. The UniFuge platform offers single-use options that support flexible volumes, ranging from small batches with the UFMicro to large production runs with the UniFuge U2K. For even higher throughput, the PowerFuge and ViaFuge stainless steel centrifuges handle volumes up to 2,400 L/hr, providing high yield and consistent performance across all production scales.

Contact Us

Stay Connected

Contact Us

Get in touch with a sales representative, request support or download our free white paper.

Contact Us